Therapeutic Goods Administration
The Therapeutic Goods Administration (TGA) is Australia's statutory regulatory authority for therapeutic goods, evaluating and monitoring medicines, medical devices, biologicals, and vaccines under the Therapeutic Goods Act 1989. It grants market authorisation via the ARTG, conducts post-market surveillance, and serves sponsors, manufacturers, healthcare professionals, and consumers.
- Company typePrivate
- Founded1989
- HeadquartersOmaha, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Therapeutic Goods Administration does
The Therapeutic Goods Administration (TGA) is Australia's statutory regulatory authority for therapeutic goods, operating as part of the Australian Government Department of Health, Disability and Ageing under the Therapeutic Goods Act 1989. TGA evaluates, assesses, and monitors therapeutic goods including prescription medicines, non-prescription medicines, vaccines, biologicals, medical devices (including in vitro diagnostics, implantable devices, and Software as a Medical Device), blood and blood products, sunscreens, and vitamins, ensuring they meet safety, efficacy, quality, and performance standards before and during market supply. The agency grants market authorisation via the Australian Register of Therapeutic Goods (ARTG), which contains 96,491+ entries, and provides pathways for accessing unapproved goods through clinical trial notifications and the Special Access Scheme. Its primary "customers" are sponsors, manufacturers, and importers of regulated products, alongside healthcare professionals and consumers.
The agency's core technology infrastructure comprises the TGA Business Services (TBS) portal for electronic submissions and ARTG management, the Australian Register of Therapeutic Goods (ARTG) as a public database, the Database of Adverse Event Notifications (DAEN) for post-market safety monitoring, the Database of Recalls, Product Alerts and Product Corrections (DRAC), and a new Unique Device Identification (UDI) system for medical device tracking. TGA is supported by an NLP-based signal detection capability applied to adverse event reports, combined with disproportionality analysis. Manufacturing licensing and GMP certification services cover both Australian and overseas manufacturers, and the agency issues infringement notices, conducts enforcement actions, and coordinates with state police on major seizures.
TGA is government-funded through parliamentary appropriations, with industry application fees and annual ARTG charges recovering a portion of regulatory costs across prescription medicines, OTC medicines, medical devices, biologicals, and other therapeutic goods. The agency does not generate commercial revenue from product sales. In December 2025, TGA was designated as a WHO Listed Authority, confirming its standing among the highest-tier international medicines regulators and enabling reliance on its decisions by other regulators and procurement bodies. The agency engages internationally with FDA, EMA, PMDA, and MHRA on regulatory harmonisation.
Therapeutic Goods Administration firmographics
Firmographics- Name
- Therapeutic Goods Administration
- Legal name
- Therapeutic Goods Administration (TGA)
- Website
- https://tga.gov.au
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- The Therapeutic Goods Administration (TGA) is Australia's statutory regulatory authority for therapeutic goods, evaluating and monitoring medicines, medical devices, biologicals, and vaccines under the Therapeutic Goods Act 1989. It grants market authorisation via the ARTG, conducts post-market surveillance, and serves sponsors, manufacturers, healthcare professionals, and consumers.
- Ownership category
- akta.pro rank
Therapeutic Goods Administration industry classification
Industry- Product category
- Pharmaceutical and Medical Device Regulatory Services
- NAICS
- Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Drug Regulators (Human Pharmaceuticals) (HLAJADAA)
- akta.pro secondary industry
- Health Technology Assessment (HTA) & Reimbursement Policy Bodies (HLAJACAF)
Keywords
Where Therapeutic Goods Administration is headquartered
LocationHeadquarters
- HQ city
- Omaha
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Therapeutic Goods Administration business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Distribution channels2 records
Marketing channels5 records
Therapeutic Goods Administration product offering
Product offeringCore offering
The Therapeutic Goods Administration (TGA) is Australia's statutory regulatory authority responsible for evaluating, assessing, and monitoring therapeutic goods — including prescription and over-the-counter medicines, vaccines, biologicals, medical devices, in vitro diagnostics, and software/AI-based medical devices — for safety, efficacy, quality, and performance. It maintains the Australian Register of Therapeutic Goods (ARTG), issues manufacturing licences and GMP certifications, processes clinical trial notifications, and conducts post-market surveillance through adverse event reporting and product recalls under the Therapeutic Goods Act 1989.
Product overview
The Therapeutic Goods Administration (TGA) operates as Australia's government regulatory authority for therapeutic goods, functioning as a platform-based regulatory system rather than a single product. The core offering is the Australian Register of Therapeutic Goods (ARTG), a comprehensive database of approved medicines, medical devices, and biologicals that can be lawfully supplied in Australia. Supporting this core registry are multiple integrated systems including the TGA Business Services portal for regulatory submissions and product management, the Special Access Scheme and Authorised Prescriber system for accessing unapproved therapeutic goods, the Database of Adverse Event Notifications (DAEN) for post-market safety monitoring, manufacturing licensing and GMP certification services, clinical trial notification system, and safety alerts and recalls system. TGA regulates prescription medicines, non-prescription medicines, vaccines, medical devices, blood and blood products, sunscreens, vitamins, and software/artificial intelligence-based medical devices, ensuring their safety, efficacy, performance and quality.
Differentiator
Problem solved
Functional benefit
Products and services
- Australian Register of Therapeutic Goods (ARTG) Public database listing all therapeutic goods that can be lawfully supplied in Australia, maintained by TGA. Contains product names, formulation details, sponsor and manufacturer information, Consumer Medicine Information (CMI), and Product Information (PI). It is for sponsors, healthcare professionals, and the general public.
- TGA Business Services Portal Electronic business services portal enabling sponsors to submit applications, manage ARTG entries, submit clinical trial notifications, report adverse events, view invoices, and maintain product registrations. It is for pharmaceutical and medical device sponsors.
- Special Access Scheme and Authorised Prescriber Online System Online system enabling healthcare practitioners to access unapproved therapeutic goods for individual patients (Special Access Scheme) or multiple patients through authorized prescribers.
- Database of Adverse Event Notifications (DAEN) Searchable database containing all adverse events reported to TGA for medicines and medical devices, supporting post-market safety monitoring and signal detection. It is for healthcare professionals, sponsors, and the general public.
- Manufacturing Licenses and GMP Certification TGA licensing system for Australian manufacturers and GMP certification for overseas manufacturers, ensuring therapeutic goods meet quality standards. It is for pharmaceutical and medical device manufacturers.
- Clinical Trial Notification System System for notifying TGA of clinical trials involving unapproved therapeutic goods, with oversight by Human Research Ethics Committees. It is for clinical trial sponsors.
- Medicine Shortages Reporting Service System for reporting and managing medicine shortages, including Section 19A approvals database for importing medicines not on ARTG to address shortages. It is for pharmaceutical sponsors and healthcare professionals.
- Safety Alerts and Recalls System System for issuing safety alerts, product recalls, and market actions when therapeutic goods pose risks to public health. It is for sponsors, healthcare professionals, and the public.
Quantifiable outcome
- WHO-designated Listed Authority status (December 2025)
- +1 more outcomes
Companies that use Therapeutic Goods Administration
Customer profileSegments4 records
Ideal customer profiles4 records
Therapeutic Goods Administration technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Therapeutic Goods Administration partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- Royal Perth HospitalcoreRoyal Perth Hospital granted TGA licences to manufacture CAR T-cells and tumour-infiltrating lymphocytes (TILs), becoming the first Australian hospital licensed to produce TILs. The Cook Labor Government expects first clinical trial and patient treatment using locally made therapies before year-end.
- Cambrex (High Point, North Carolina facility)supportingCambrex's High Point facility successfully completed pre-approval inspections by US FDA, Japan's PMDA, and Australia's TGA. The site, expanded in 2023 by $38 million, will produce approved APIs for the three markets and supports smaller-scale commercial production including orphan drugs.
- Monash UniversitycoreMonash University signed Memorandum of Understanding with TGA to join its Academic Outreach Program, establishing collaboration in pharmaceutical regulatory science and therapeutics development. First research activity involves evaluating methods to detect toxic contaminants such as ethylene glycol and diethylene glycol in oral liquid medicines, particularly for low-resource settings. This addresses global safety concerns following over 400 child deaths in Uzbekistan, Gambia, Indonesia, and India due to falsified ingredients entering supply chains since 2022.
- Australian Digital Health Agency (ADHA)supportingTGA participates in ADHA's National Clinical Governance Committee for Digital Health (NCGC-DH), which oversees AI, virtual care, and telehealth in healthcare settings. TGA supports the committee alongside Australian Commission on Safety and Quality in Health Care, focusing on safe access to My Health Record, quality in virtual care, and safe AI implementation in healthcare.
- World Health Organization (WHO)coreWHO formally designated TGA as a WHO Listed Authority (WLA), an internationally recognized status for medicines regulators. This designation confirms TGA ensures medicines and vaccines meet highest international standards for quality, safety, and efficacy. The WLA framework enables other regulators and procurement bodies to rely on TGA's decisions, reducing duplication of regulatory work and accelerating global access to essential medicines and vaccines.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Therapeutic Goods Administration competitors and assessment
Company assessmentDirect peers
- U.S. Food and Drug Administration (FDA): United States federal agency regulating drugs, biologics, and medical devices. Most direct international counterpart to TGA, sharing scope over prescription medicines, vaccines, IVDs, and Software as a Medical Device; both operate pre-market authorisation plus post-market surveillance with comparable scientific guideline adoption.
- European Medicines Agency (EMA): European Union regulatory body for human and veterinary medicines, with similar centralised marketing authorisation, GMP certification, and pharmacovigilance functions. Operates in a multi-country setting with reliance pathways that increasingly intersect with WHO-listed authorities such as TGA.
- Medicines and Healthcare products Regulatory Agency (MHRA): United Kingdom regulator for medicines, medical devices, and blood components. Closely comparable scope (including SaMD/AI as a medical device), with public consultation, special access schemes, and post-market adverse event reporting analogous to TGA's ARTG/DAEN structures.
- Pharmaceuticals and Medical Devices Agency (PMDA): Japan's regulator for pharmaceuticals and medical devices, conducting scientific reviews for marketing authorisation and post-market safety. Comparable to TGA in its simultaneous coverage of prescription drugs, regenerative medicines, and medical devices including AI-enabled SaMD.
- Health Canada: Canadian federal authority responsible for regulation of therapeutic products, medical devices, and clinical trials. Operates a comparable risk-based classification framework, post-market surveillance, and Special Access Programme analogous to TGA's Special Access Scheme.
- Swissmedic: Swiss national regulator for therapeutic products with marketing authorisation, clinical trial oversight, and post-market pharmacovigilance functions. Frequently cited alongside TGA as a similarly sized mature regulator whose decisions are relied upon internationally.
- National Medical Products Administration (NMPA): China's regulator for drugs, medical devices, cosmetics, and IVDs. Comparable in its end-to-end authority over approvals, GMP inspections, and adverse event reporting, with growing reliance relationships with WHO-listed authorities.
- ANVISA: Brazil's health regulatory agency with responsibility for drugs, biologics, medical devices, and post-market surveillance. Similar scale and statutory authority; increasingly relevant peer as TGA engages with international harmonisation efforts under the WHO Listed Authority framework.
Regional players
- Health Sciences Authority (HSA), Singapore: Singapore's regulator for therapeutic products, medical devices, and complementary health products. Comparable in scope but smaller in scale; HSA participates in regional reliance networks that frequently intersect with TGA-approved products seeking Asia-Pacific market entry.
- Medsafe (New Zealand): New Zealand's medicines and medical devices regulator, administered under the Medsafe unit of the Ministry of Health. Operates as a direct smaller-scale counterpart, often relying on TGA evaluations and sharing signal-detection intelligence due to trans-Tasman regulatory proximity.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Therapeutic Goods Administration social profiles
Digital presenceTherapeutic Goods Administration compliance and trust
Trust signalCompliance1 record
Therapeutic Goods Administration financial estimates
Financial estimateRevenue estimate
Valuation estimate
Therapeutic Goods Administration leadership team
Management profileNumber of profiles
Profiles1 record
Therapeutic Goods Administration funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Therapeutic Goods Administration M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Therapeutic Goods Administration
What does Therapeutic Goods Administration do?
The Therapeutic Goods Administration (TGA) is Australia's statutory regulatory authority responsible for evaluating, assessing, and monitoring therapeutic goods — including prescription and over-the-counter medicines, vaccines, biologicals, medical devices, in vitro diagnostics, and software/AI-based medical devices — for safety, efficacy, quality, and performance. It maintains the Australian Register of Therapeutic Goods (ARTG), issues manufacturing licences and GMP certifications, processes clinical trial notifications, and conducts post-market surveillance through adverse event reporting and product recalls under the Therapeutic Goods Act 1989.
Is Therapeutic Goods Administration a public or private company?
Therapeutic Goods Administration is a private company. It is classified as state government owned and is currently operating.
When was Therapeutic Goods Administration founded?
Therapeutic Goods Administration was founded in 1989. It employs 251 to 500 people.
Where is Therapeutic Goods Administration based?
Therapeutic Goods Administration is headquartered in Omaha, United States, in the North America region.
Who are Therapeutic Goods Administration's main competitors?
Direct peers on record are U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic, National Medical Products Administration (NMPA) and ANVISA. Regional players are Health Sciences Authority (HSA), Singapore and Medsafe (New Zealand).
Does Therapeutic Goods Administration have an API?
No public API is recorded for Therapeutic Goods Administration.
What industry is Therapeutic Goods Administration in?
Therapeutic Goods Administration's product category is Pharmaceutical and Medical Device Regulatory Services. Its primary akta.pro industry code is HLAJADAA, Drug Regulators (Human Pharmaceuticals), with a secondary code of HLAJACAF, Health Technology Assessment (HTA) & Reimbursement Policy Bodies. Its NAICS code is 524292 and its SIC code is 8000.